Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.54 |
| ▸ | NT5E | P21589 | 3/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12084871 | 1.00 | ADORA2A (0.54) | ADORA2AADORA3ADORA1NT5EADORA2B | |
| SCHEMBL2091877 | 0.88 | ADORA2A (0.56) | ADORA2AADORA3ADORA1NT5EADORA2B | |
| SCHEMBL2091875 | 0.88 | ADORA2A (0.56) | ADORA2AADORA3ADORA1NT5EADORA2B | |
| SCHEMBL241197 | 0.88 | ADORA2A (0.56) | ADORA2AADORA3ADORA1NT5EADORA2B | |
| SCHEMBL1911346 | 0.85 | ADORA3 (0.50) | ADORA2AADORA3ADORA1NT5EADORA2B | |
| SCHEMBL12084902 | 0.83 | ADORA2A (0.49) | ADORA2AADORA3ADORA1NT5EADORA2B | |
| SCHEMBL1412472 | 0.83 | ADORA2A (0.55) | ADORA2AADORA3ADORA1NT5EADORA2B | |
| SCHEMBL3118651 | 0.83 | ADORA2A (0.55) | ADORA2AADORA3ADORA1NT5EADORA2B | |
| SCHEMBL1412375 | 0.83 | ADORA2A (0.55) | ADORA2AADORA3ADORA1NT5EADORA2B | |
| SCHEMBL242820 | 0.82 | ADORA2A (0.57) | ADORA2AADORA3ADORA1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885ADORA1 1271/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885ADORA1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.